Search research articles
Contact Us
Filters
Showing results (1-10 of 143) with videos related to
Page
of 15
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 9, 2022
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax
Lydia Scarfò
Blood
|
January 12, 2023
COVID-19 prophylaxis: half-full or half-empty glass?
Lydia Scarfò, Antonio Cuneo
Seminars in Oncology
|
April 5, 2016
What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges
Lydia Scarfò, Paolo Ghia
Hemasphere
|
November 15, 2019
Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Time to Retire?
Lydia Scarfò, Alessandra Tedeschi
Blood
|
August 4, 2022
CLL and COVID-19: light at the end of the tunnel?
Lydia Scarfò, Yair Herishanu
Immunology Letters
|
October 8, 2013
Reprogramming cell death: BCL2 family inhibition in hematological malignancies
Lydia Scarfò, Paolo Ghia
Current Opinion in Oncology
|
October 9, 2019
The evolving treatment landscape of chronic lymphocytic leukemia
Luana Schiattone, Paolo Ghia, Lydia Scarfò
Cancer Journal (Sudbury, Mass.)
|
November 26, 2019
Relevance of Minimal Residual Disease in the Era of Targeted Agents
Silvia Heltai, Paolo Ghia, Lydia Scarfò
Hematology/Oncology Clinics of North America
|
April 9, 2013
MBL versus CLL: how important is the distinction?
Lydia Scarfò, Claudia Fazi, Paolo Ghia
Seminars in Cancer Biology
|
September 4, 2013
Monoclonal B cell lymphocytosis and "in situ" lymphoma
Kennosuke Karube, Lydia Scarfò, Elias Campo, et al.
Page
of 15
Search research articles
Search
Showing results (1-10 of 143) with videos related to
Sort By:
Page
of 15
Hematology. American Society of Hematology. Education Program
|
December 9, 2022
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax
Lydia Scarfò
Blood
|
January 12, 2023
COVID-19 prophylaxis: half-full or half-empty glass?
Lydia Scarfò, Antonio Cuneo
Seminars in Oncology
|
April 5, 2016
What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges
Lydia Scarfò, Paolo Ghia
Hemasphere
|
November 15, 2019
Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Time to Retire?
Lydia Scarfò, Alessandra Tedeschi
Blood
|
August 4, 2022
CLL and COVID-19: light at the end of the tunnel?
Lydia Scarfò, Yair Herishanu
Immunology Letters
|
October 8, 2013
Reprogramming cell death: BCL2 family inhibition in hematological malignancies
Lydia Scarfò, Paolo Ghia
Current Opinion in Oncology
|
October 9, 2019
The evolving treatment landscape of chronic lymphocytic leukemia
Luana Schiattone, Paolo Ghia, Lydia Scarfò
Cancer Journal (Sudbury, Mass.)
|
November 26, 2019
Relevance of Minimal Residual Disease in the Era of Targeted Agents
Silvia Heltai, Paolo Ghia, Lydia Scarfò
Hematology/Oncology Clinics of North America
|
April 9, 2013
MBL versus CLL: how important is the distinction?
Lydia Scarfò, Claudia Fazi, Paolo Ghia
Seminars in Cancer Biology
|
September 4, 2013
Monoclonal B cell lymphocytosis and "in situ" lymphoma
Kennosuke Karube, Lydia Scarfò, Elias Campo, et al.
Page
of 15